Onesource Specialty Pharma Ltd. experienced a significant decline in its share price, dropping as much as 18% following the release of its December quarter results. The primary reason for this decline was the delay in regulatory approval for semaglutide in Canada, which had a substantial impact on the company's revenue and profitability.
The delay in regulatory approval for semaglutide in Canada led to a sharp revenue shortfall for Onesource Specialty Pharma. The company's revenue for Q3 FY26 was ₹290.34 crore, a decline of 23% quarter-on-quarter and 26% year-on-year.
Operating expenses increased by 1% quarter-on-quarter and 9% year-on-year, further pressuring margins. The EBITDA for the quarter was ₹17.322 crore, a significant drop from ₹106.495 crore in the previous quarter and ₹141.9 crore in the same quarter last year.
The company reported a loss of ₹88.699 crore, compared to a profit of ₹10.485 crore in the previous quarter.
Management described Q3 as a subdued quarter but maintained that underlying demand trends remain intact. The order book continues to show an upward trajectory, while interest in the biologics segment is rising. The company has also onboarded another biosimilar player, reinforcing confidence in the platform.
Read More: Adani Green Energy's Q3 FY26 Earnings Results: Revenue up by 7.6% YoY!
The company's financial performance for Q3 FY26 was significantly impacted by the semaglutide delay. Revenue declined to ₹290.34 crore, operating expenses increased to ₹273.018 crore, and EBITDA margins dropped to 6.0%. The company reported a loss of ₹88.699 crore for the quarter.
As of January 27, 2026, at 12:15 PM, OneSource Specialty Pharma share price on NSE was trading at ₹1,187.50 down by 17.10% from the previous closing price.
Onesource Specialty Pharma Ltd. faced a challenging quarter due to the delay in semaglutide approval in Canada, leading to a significant decline in revenue and profitability. The company's share price dropped by 18% as a result. Management remains confident in the underlying demand trends and the company's long-term growth prospects.
Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks. Read all the related documents carefully before investing.
Published on: Jan 27, 2026, 12:58 PM IST
Team Angel One
We're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
